→ One of Wednesday’s big movers was Spectrum Pharmaceuticals $SPPI, which touted the preliminary results from a small Phase II study of its drug poziotinib in EGFR exon 20 mutant non-small cell lung cancer. All 11 patients evaluable so far have responded in some fashion, they said, spurring plans to meet with regulators to evaluate their shot at an accelerated approval.
→ Jeff Williams, the co-founder and CEO of the CRO Clinipace Worldwide is taking an expanded advisory role with the company’s board and handing over his responsibilities to Jason Monteleone, who takes over as the new CEO. Williams will remain a director and will focus on strategic initiatives.
→ Corbus Pharma shares $CRBP surged 12% by mid-morning Thursday after the biotech reported that researchers had hit a significant outcome for their experimental drug anabasum for dermatomyositis. The drug achieved a 9.3 point drop in the skin disease severity rating, compared to 3.7 for the placebo arm. That hit a p-value of 0.04. The study was small, with 22 patients.
→ Forge Therapeutics and Evotec have expanded their existing strategic alliance and launched the BLACKSMITH platform “to discover a broader range of therapeutics targeting metalloenzymes.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,000+ biopharma pros who read Endpoints News by email every day.Free Subscription